Some migraine patients mistakenly think their medication is not addictive: 36 percent of patients taking barbiturates or opioids as their primary migraine prescription medication said the phrase "not addictive" describes their medication "extremely" or "very" well, according to the survey.
Few physicians surveyed prescribe barbiturates or opioids (2% and 1% respectively) as a first-line acute treatment for migraines, but general practitioners are more likely than neurologists to prescribe opioids as a second-line treatment, the survey found. Twenty-five percent of general practitioners say they would prescribe opioids as a second-line therapy for migraines, compared with just 7 percent of neurologists.
"Though it's encouraging that the survey showed 53 percent of migraine patients are now on triptans, an approved drug class, the fact that 20 percent of patients continue to take medications unapproved to treat migraine indicates that additional physician education could be helpful" said Suzanne Simons, executive director of the National Headache Foundation.
Simple Steps to Achieving Optimal Migraine Treatment
While there is no cure for migraines, taking the right medication below to effectively treat your migraine will minimize how they affect your daily life. Here are a few steps you can take to help optimize your migraine treatment.
-- Observe. Make note of any side effects that you experience from your migraine medication which may affect your daily activities. -- Communicate. Keep a headache journal or diary. The journal may include when the headache occurred, its severity, duration, location and whether the medication you took to treat it was effective. You can download a free headache diary at http://www.headaches.org -- Use self-management techniques -- There are ways to manage your
Page: 1 2 3 4 5 6
Related medicine technology :
1. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
2. Trexima (Sumatriptan/Naproxen Sodium) Demonstrated Migraine-Free Response Across Multiple Attacks
3. NuPathe Reports Positive Phase One Results for NP101 Transdermal Therapy for Acute Migraine
4. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
5. Trexima (Sumatriptan/Naproxen Sodium) Provided Relief of Both Traditional and Non-traditional Migraine Symptoms
6. Trexima (Sumatriptan/Naproxen Sodium) Demonstrated Efficacy Across Multiple Migraine Attacks
7. Addex Reports Positive Results in Phase IIa Clinical Trial With ADX10059 in Migraine
8. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
9. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
10. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery